Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transient receptor potential canonical 3 channel (TRPC3) is a member of the transient receptor potential (TRP) channel family and functions as a nonselective, Ca^2+-permeable cation channel. It is broadly expressed in various tissues including brain, heart, endocrine glands, and smooth muscle, and is crucial for cellular calcium signaling. TRPC3 is directly activated by diacylglycerol downstream of G protein-coupled receptor activation and regulated by endogenous lipids, Ca^2+ ions, and protein interactions. Its physiological roles include mediation of store-operated and receptor-operated calcium entry, mitochondrial Ca^2+ uptake regulation, and protein scaffolding at the plasma membrane. TRPC3 is implicated in several pathologies, notably cardiovascular diseases (such as hypertension and cardiac fibrosis), neurodegenerative diseases, cancer, and inflammation, making it a significant therapeutic target[2][4][5][6][7][3][1].
Channel blockers or modulators alter calcium influx by inhibiting or activating TRPC3-mediated cation flow; Antagonists prevent activation by endogenous lipids or diacylglycerol
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transient receptor potential canonical 3 channel (TRPC3).